Related Experiment Video
Updated: Nov 28, 2025
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles
Justas Lazutka1, Karolis Simutis1, Paulius Matulis1
1Department of Eukaryote Gene Engineering, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio al. 7, Vilnius, Lithuania.
Abstract:
Human parvovirus 4 (PARV4) is a novel tetraparvovirus that was isolated from intravenous drug users in 2005. Recombinant PARV4 capsid protein VP2 can form stable virus-like particles (VLPs) in yeast. These VLPs could act as antigen carriers during vaccine development. Therefore, the information about PARV4 VP2 VLP antigenic sites could advance further research in this area. In this work, human parvovirus 4 VLPs obtained from yeast were used to generate monoclonal antibodies (mAbs) in mice. Epitope mapping of the obtained mAbs showed at least three distinct antigenic sites of the VP2 protein. On top of that, molecular cloning was used to replace PARV4 VP2 antigenic sites with heterologous peptides. The chimeric PARV4 VLPs bearing polyhistidine inserts obtained from yeast were observed using electron microscopy while polyhistidine-specific antibodies detected heterologous peptides of the chimeric VP2 proteins.
Insights
Researchers identified key antigenic sites on human parvovirus 4 (PARV4) VP2 protein using virus-like particles (VLPs). This discovery advances vaccine development by mapping epitopes and creating chimeric VLPs for potential antigen carriers.
Area of Science:
- Virology
- Immunology
- Biotechnology
Background:
- Human parvovirus 4 (PARV4), a novel tetraparvovirus, was identified in 2005.
- Recombinant PARV4 capsid protein VP2 forms stable virus-like particles (VLPs) in yeast, presenting potential as antigen carriers for vaccine development.
Purpose of the Study:
- To characterize the antigenic sites of PARV4 VP2 VLPs.
- To explore the potential of modifying PARV4 VLPs for vaccine applications.
Main Methods:
- Generation of monoclonal antibodies (mAbs) against PARV4 VLPs.
- Epitope mapping of mAbs to identify antigenic sites on VP2.
- Molecular cloning to replace identified antigenic sites with heterologous peptides.
- Production of chimeric PARV4 VLPs in yeast.
- Electron microscopy and antibody detection for characterizing chimeric VLPs.
Main Results:
- At least three distinct antigenic sites on the PARV4 VP2 protein were identified through epitope mapping.
- Chimeric PARV4 VLPs were successfully constructed with inserted heterologous peptides at specific antigenic sites.
- Electron microscopy confirmed the structure of chimeric VLPs, and polyhistidine-specific antibodies detected the inserted peptides.
Conclusions:
- The study successfully mapped antigenic sites on PARV4 VP2 VLPs.
- The creation of chimeric VLPs demonstrates a method for displaying heterologous peptides, advancing their potential as antigen carriers in vaccine development.
